Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | FABP3 | P05413 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | NR5A2 | O00482 | 1/20 | 0.47 |
| ▸ | NR5A1 | Q13285 | 1/20 | 0.47 |
| ▸ | LPAR1 | Q92633 | 6/20 | 0.47 |
| ▸ | ENPP2 | Q13822 | 4/20 | 0.47 |
| ▸ | LPAR2 | Q9HBW0 | 3/20 | 0.47 |
| ▸ | LPAR4 | Q99677 | 2/20 | 0.47 |
| ▸ | LPAR5 | Q9H1C0 | 2/20 | 0.47 |
| ▸ | LPAR3 | Q9UBY5 | 2/20 | 0.47 |
| ▸ | CES2 | O00748 | 1/20 | 0.47 |
| ▸ | LPAR6 | P43657 | 1/20 | 0.47 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | DAGLA | Q9Y4D2 | 1/20 | 0.46 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23166803 | 1.00 | ALDH1A1 (0.53) | ALDH1A1FABP3SMN1; SMN2NR5A2NR5A1 | |
| SCHEMBL23091273 | 1.00 | ALDH1A1 (0.53) | ALDH1A1FABP3SMN1; SMN2NR5A2NR5A1 | |
| SCHEMBL3182833 | 0.92 | FABP3 (0.54) | FABP3SMN1; SMN2NR5A2NR5A1 | |
| SCHEMBL22721397 | 0.92 | FABP3 (0.54) | FABP3SMN1; SMN2NR5A2NR5A1 | |
| SCHEMBL1768918 | 0.92 | FABP3 (0.54) | FABP3SMN1; SMN2NR5A2NR5A1 | |
| SCHEMBL1341976 | 0.92 | FABP3 (0.54) | FABP3SMN1; SMN2NR5A2NR5A1 | |
| SCHEMBL2638014 | 0.92 | FABP3 (0.54) | FABP3SMN1; SMN2NR5A2NR5A1 | |
| SCHEMBL31432721 | 0.92 | FABP3 (0.54) | FABP3SMN1; SMN2NR5A2NR5A1 | |
| SCHEMBL3983857 | 0.92 | FABP3 (0.54) | FABP3SMN1; SMN2NR5A2NR5A1 | |
| SCHEMBL6666152 | 0.91 | FABP3 (0.52) | FABP3SMN1; SMN2NR5A2NR5A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 160 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11931699-B2 | Aquaporin Z integrated membrane production method | ISTANBUL TEKNIK UNIVERSITESI (TR) | 2024-03-19 | — | — | US | claimed |
| US-20220274068-A1 | AQUAPORIN Z INTEGRATED MEMBRANE PRODUCTION METHOD | ISTANBUL TEKNIK UNIVERSITESI (TR) | 2022-09-01 | — | — | US | claimed |
| US-10844109-B2 | Method for producing erythrocyte proteins | INSTITUT NATIONAL TRANSFUSION SANGUINE (FR) | 2020-11-24 | — | — | US | claimed |
| WO-2014057432-A9 | MULTICOMPONENT LIPID NANOPARTICLES AND PROCESSES FOR THE PREPARATION THEREOF | UNIVERSITA' DEGLI STUDI DI ROMA "LA SAPIENZA" (IT) | 2014-05-30 | — | — | WO | claimed |
| US-20260132383-A1 | COMPOSITIONS AND METHODS FOR DELIVERY OF IMMUNE CELLS TO TREAT UN-RESECTABLE OR NON-RESECTED TUMOR CELLS AND TUMOR RELAPSE | FRED HUTCHINSON CANCER CENTER (US) | 2026-05-14 | — | — | US | disclosed |
| US-20260097044-A1 | ION PAIR LIQUID CRYSTAL FORMULATIONS FOR LONG-ACTING INJECTABLES OF POORLY SOLUBLE DRUGS | FORDOZ PHARMA CORP. (US) | 2026-04-09 | — | — | US | disclosed |
| US-20260097120-A1 | INDUCTION OF STEM-LIKE ACTIVATED T CELLS | PHIO PHARMACEUTICALS CORP. (US) | 2026-04-09 | — | — | US | disclosed |
| US-12584114-B2 | Compositions and methods for delivery of immune cells to treat un-resectable or non-resected tumor cells and tumor relapse | FRED HUTCHINSON CANCER CENTER (US) | 2026-03-24 | — | — | US | disclosed |
| EP-4694884-A2 | METHODS OF USE OF A LIPOSOMAL COMPOSITION COMPRISING AN ATR INHIBITOR | Jazz Pharmaceuticals Therapeutics, Inc. (US) | 2026-02-18 | — | — | EP | disclosed |
| EP-4694883-A2 | COMBINATIONS COMPRISING AN ATR INHIBITOR AND A PARP INHIBITOR AND METHODS OF USE THEREOF | Jazz Pharmaceuticals Therapeutics, Inc. (US) | 2026-02-18 | — | — | EP | disclosed |
| US-12544344-B2 | Topical delivery of nucleic acid compounds | PHIO PHARMACEUTICALS CORP. (US) | 2026-02-10 | — | — | US | disclosed |
| EP-4636090-A1 | UTR FOR IMPROVING TRANSLATION EFFICIENCY AND/OR STABILITY OF RNA MOLECULE AND USE THEREOF | Shenzhen Shenxin Biotechnology Co., Ltd. (CN) | 2025-10-22 | — | — | EP | disclosed |
| US-20110237522-A1 | NEUTRAL NANOTRANSPORTERS | PHIO PHARMACEUTICALS CORP. | 2011-09-29 | — | — | US | disclosed |
| WO-2011109698-A1 | FORMULATIONS AND METHODS FOR TARGETED DELIVERY TO PHAGOCYTE CELLS | RXI PHARMACEUTICALS CORPORATION (US) | 2011-09-09 | — | — | WO | disclosed |
| EP-2342340-A1 | RNA INTERFERENCE IN SKIN INDICATIONS | Rxi Pharmaceuticals Corporation (US) | 2011-07-13 | — | — | EP | disclosed |
| EP-2340310-A2 | REDUCED SIZE SELF-DELIVERING RNAI COMPOUNDS | Rxi Pharmaceuticals Corporation (US) | 2011-07-06 | — | — | EP | disclosed |
| EP-2340309-A2 | NEUTRAL NANOTRANSPORTERS | Rxi Pharmaceuticals Corporation (US) | 2011-07-06 | — | — | EP | disclosed |
| WO-2010033246-A1 | RNA INTERFERENCE IN SKIN INDICATIONS | RXI PHARMACEUTICALS CORPORATION (US) | 2010-03-25 | — | — | WO | disclosed |
| WO-2010033247-A2 | REDUCED SIZE SELF-DELIVERING RNAI COMPOUNDS | RXI PHARMACEUTICALS CORPORATION (US) | 2010-03-25 | — | — | WO | disclosed |
| WO-2010033248-A2 | NEUTRAL NANOTRANSPORTERS | RXI PHARMACEUTICALS CORPORATION (US) | 2010-03-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260097120-A1 | INDUCTION OF STEM-LIKE ACTIVATED T CELLS | CD274, PDCD1LG2, ICOS | ALDH1A1 1032/4885FABP3 1994/4885SMN1; SMN2 778/4885 |
| US-12584114-B2 | Compositions and methods for delivery of immune cells to treat un-resectable or non-resected tumor cells and tumor relapse | ICOS, CD4, CD69 | ALDH1A1 3754/4885FABP3 2648/4885SMN1; SMN2 3333/4885 |
| US-20260132383-A1 | COMPOSITIONS AND METHODS FOR DELIVERY OF IMMUNE CELLS TO TREAT UN-RESECTABLE OR NON-RESECTED TUMOR CELLS AND TUMOR RELAPSE | ICOS, CD4, CD47 | ALDH1A1 3505/4885FABP3 2721/4885SMN1; SMN2 2703/4885 |
| US-12544344-B2 | Topical delivery of nucleic acid compounds | METTL16, NSUN2, RNMT | ALDH1A1 3205/4885FABP3 3784/4885SMN1; SMN2 563/4885 |
| US-20260097044-A1 | ION PAIR LIQUID CRYSTAL FORMULATIONS FOR LONG-ACTING INJECTABLES OF POORLY SOLUBLE DRUGS | SSB, LTB4R2, THRB | ALDH1A1 3674/4885FABP3 292/4885SMN1; SMN2 1909/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.